http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2235164-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0eb3e981dd7eddec8673b4e19b35708b |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-24221 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-525 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-24222 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-24234 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-29 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-29 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-00 |
| filingDate | 2008-12-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9cf07a8be2eed0dca98acb7228b841aa http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_14edc1aa97d4272efef81b06886de07c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7d792353c61ed2dcc6982e24117a94ac http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e4d6e6804e20534b2c579071d1872bda http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_846f0fdbe29c3c4e38acfb4a1d574b7f |
| publicationDate | 2010-10-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-2235164-A1 |
| titleOfInvention | Efficient cell culture system for hepatitis c virus genotype 1a and 1b |
| abstract | The present inventors developed hepatitis C virus la/2a and lb/2a intergenotypic recombinants in which the JFHl structural genes (Core, El and E2), p7 and NS2 were replaced by the corresponding genes of the genotype Ia reference strain H77C or TN or the corresponding genes of the genotype Ib reference strain J4. Sequence analysis of recovered la/2a and lb/2a recombinants from 2 serial passages and subsequent reverse genetic studies revealed adaptive mutations in e.g. p7, NS2 and/or NS3. In addition, the inventors demonstrate the possibility of using adaptive mutations identified for one HCV isolate in generating efficient cell culture systems for other isolates by transfer of mutations across isolates, subtypes or major genotypes. Furthermore neutralization studies showed that viruses of e.g. genotype 1 were efficiently neutralized by genotype Ia, 4a and 5a serum, an effect that could be utilized e.g. in vaccine development and immunological prophylaxis. The inventors in addition demonstrate the use of the developed systems for screening of antiviral substances in vitro and functional studies of the virus, e.g. identification of receptors required for HCV entry, |
| priorityDate | 2007-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 226.